Transplantation in HIV Michelle Roland, MD Assistant Professor of Medicine UCSF Positive Health Program at SFGH.

Slides:

Advertisements

Similar presentations

Hepatitis B & Hepatitis C in HIV

Advertisements

HIV 101 Review Evaluation Center for HIV and Oral Health Boston University School of Public Health Health & Disability Working Group.

Prolonged Diabetes Reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates Hering et al, Nature.

PROMISE Introduction to PROMISE Protocol May 6, 2009.

CANOVA South Africa 17 November 2005 Presented By: Dr M Mojapelo.

Monica Colvin-Adams, MD Assistant Professor of Medicine Advanced Heart Failure and Transplantation University of Minnesota Compassionate Allowances Outreach.

Optimizing lung transplant outcomes in the adult and pediatric patient. Cynthia S. Herrington, MD Associate Professor of Surgery Keck School of Medicine.

HIV in Suriname Ministry of Health Suriname M.Sigrid Mac Donald – Ottevanger, MD Focal point HIV Treatment and Care, NAP.

Sponsored by the University of California, San Francisco

1 Is Managed Care Superior to Traditional Fee-For-Service among HIV-Infected Beneficiaries of Medicaid? David Zingmond, MD, PhD UCLA Division of General.

The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.

Tolerance Induction after Kidney Transplantation Stephan Busque MD M Sc FRCSC Director, Adult Kidney and Pancreas Transplantation Program Stanford University.

HIV Organ Policy Equity (HOPE) Act Research Criteria: follow-up discussion Advisory Committee on Organ Transplantation April 13, 2015.

Therapeutic Response to Azacitidine (AZA) in Patients with Secondary Myelodysplastic Syndromes (sMDS) Enrolled in the AVIDA Registry 1 Prospective Trial.

Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.

Clinical Care of HIV, AIDS and Opportunistic Infections

Living Donor Liver Transplantation in PSC Patients Giuliano Testa, MD, FACS, MBA Surgical Director, Living Donor Liver Transplantation Baylor University.

Liver Transplants for PLWHA in Spain 10 years of activism Xavier Franquet Grupo de Trabajo sobre Tratamientos del VIH (gTt) Foro.

Hepatitis C+ Recipients: Considerations for Exclusion Emily A. Blumberg, M.D.

HIV i-Base: SMART Study & CROI Feedback UK-CAB - Feb 2006 UK-CAB 24 February 2006 CROI Feedback: SMART Study Simon Collins.

HIV/renal studies (CHIC) Baseline renal function as predictor of HIV/renal disease progression –Death, opportunistic infection –Severe chronic kidney disease.

Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,

I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.

INTRODUCTION Evaluation of Outcomes in Patients Starting Antiretroviral Therapy During Hospitalization Leigh E. Efird, PharmD 1, Manish Patel, PharmD 1,

Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.

HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.

History of Opportunistic Complications: Should This Remain An Exclusionary Criterion? Kathleen E. Squires, M.D. Associate Professor of Medicine Keck School.

Ethics and Policy Conference Day One Summary. Goals of the Meeting Educate people about the status of various protocol decisions Define areas where we.

Prophylaxis of Opportunistic Infections

ORGAN TRANSPLANTATION: PERSONS WITH DETECTABLE HIV VIRAL LOAD Margaret Ragni, MD University of Pittsburgh.

HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients Roger Bedimo, MD; Henning Drechsler, MD; Song Zhang, PhD;

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

Transplantation in HIV+ Recipients Ron Shapiro, M.D. THOMAS E. STARZL TRANSPLANTATION INSTITUTE UNIVERSITY OF PITTSBURGH.

Open-label W24 ≥ 18 years Chronic HCV infection All genotypes HCV RNA ≥ 10,000 IU/ml Liver transplantation months earlier Child Pugh ≤ 7 and MELD.

RAD Immunosuppression in Heart Transplant Recipients Duke Heart Failure Research Pager:

Liver transplantation for HCV infection R3 양 인 호 /Prof 김 병 호.

Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.

Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection The INSIGHT START Study Group Ben Andres Oct 15, 2015.

Is it possible to predict New Onset Diabetes After Transplantation (NODAT) in renal recipients using epidemiological data alone? Background NODAT is an.

United States Organ Transplantation SRTR & OPTN Annual Data Report, 2011 Kidney.

Previous SVR With Interferon-Based Therapy for HCV Lowers Risk of Hepatotoxicity in HIV/HCV-Coinfected Individuals on Antiretroviral Therapy Slideset on:

HIV Infection Increases Risk of ASCUS and Subsequent Development of SILs Slideset on: Duerr A, Paramsothy P, Jamieson DJ, et al. Effect of HIV infection.

Rapid Fibrosis and Significant Histologic Recurrence of Hepatitis C After Liver Transplant Is Associated With Higher Tumor Recurrence Rates in Hepatocellular.

Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

Genotype 1 HCV infection Stable immunosuppressive therapy

ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.

ADVERSE OUTCOMES OF TREATING HIV-TB

Phase 3 Treatment-Naïve and Treatment-Experienced

Attitude of HIV patients toward organ transplant between HIV patients: A Cross - Sectional questionnaire survey Dr H Taha [1], Dr Katie Newby [2], Mr.

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

HCV & liver transplantation

Validating Definitions of Antiretroviral Treatment Failure in Malawi

Clinical outcome after SVR: Veterans Affairs

Kidney Transplants in HIV Positive Patients

The Aging Liver in the Aging HIV and HCV Patients

Simeprevir in HIV Coinfection, GT-1 C212 Trial

When to START During an OI

Switch to LPV/r monotherapy

Anthony D Harries Ministry of Health, Malawi

Switch to LPV/r monotherapy

ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.

Switch to LPV/r monotherapy

Core Competency 1: Epidemiologic Background of HIV/HCV Co-infection in the United States Lesson 2: Morbidity and Mortality in HCV Co-infected People Living.

Khai Hoan Tram, Jane O’Halloran, Rachel Presti, Jeffrey Atkinson

Presentation transcript:

Transplantation in HIV Michelle Roland, MD Assistant Professor of Medicine UCSF Positive Health Program at SFGH

Background HIV-infected patients have been excluded from consideration for transplantation because: 1. Morbidity too high to justify organ use 2. Immunosuppression might accelerate HIV disease Mortality is reduced with HAART Prospective study will evaluate: 1. Effect of immunosuppression on survival and HIV disease 2.Effect of HIV on graft survival 3. Drug interactions between PI/NNRTI and immunosuppressives Many centers transplanted patients prior to the study

Methods Prospective analysis of enrolled subjects + Retrospective review of recipients at study centers “Eligible” subjects: No opportunistic infection history CD4 > 200 kidney; >100 liver HIV RNA < 50 kidney, liver or unable to tolerate ARVs in liver but post-transplant suppression predicted “Ineligible” subjects: Did not meet 1 or more criteria above

Results: Baseline 41 “Eligible” Subjects 22 Kidney and 19 Liver 8 “Ineligible” Subjects undiagnosed HIV, HIV RNA > 50 (K), low CD4, altered MS, history of OI/ON Baseline CD4+ T Cell Counts Kidney: 455 ( ) Liver:321 ( ) Baseline HIV-1 RNA Liver: <50 (< ,776)

Results: Outcomes Median follow-up279 days ( ) Deaths1 kidney + 3 liver - recurrent hepatitis C - rejection after PI stopped - post-op complications x 2 Opportunistic Complications 1 liver + 1 kidney - CMV esophagitis - candida esophagitis

Results: Outcomes CD4+ T Cell Counts Kidney 460 ( ) Liver296 ( ) HIV-1 RNA Kidney< 50 (< ,343) Liver <50 (< ) Re-transplantation1 liver Graft loss1 kidney Additional rejection36% kidney + 11% liver

Outcomes: Ineligible Subjects Undiagnosed HIVdeath (MAC< PML) Altered MSdeath (PML) HIV RNA > 50 (K)all <50 or < 400 Low CD4stable 76 --> 102 History of OI/ON (PCP + CMV; KS + CMV)no recurrence at 15 months and 5 weeks

Conclusions Patient survival is comparable to UNOS data at 1 year 95% kidney subjectsUNOS = 94.8% cadaver/97.6% living 84% liver subjectsUNOS = 87.9% No significant HIV disease progression in selected pts 2 OI s could be due to HIV or immunosuppression Stable CD4+ T-cell counts and suppressed HIV-1 RNA There is HIV progression with advanced disease Graft survival is comparable to UNOS data at 1 year 89% kidney subjectsUNOS = 89.4% cadaver/94.5% living 84% liver subjectsUNOS = 81.4%